Nicaragua modernized its medical device regulatory framework in 2025 with mandatory technical standard NTON 24001, which classifies human-use devices into four risk classes and is overseen by the Ministry of Health (MINSA) through the National Health Regulation Authority (ANRS). With institutional CIRE ethics review, ISO 14155 alignment, and bioaccess®'s coordination, sponsors can generate FDA-submissible first-in-human data at ~30% lower cost than US/EU programs.
Nicaragua is an emerging Central American clinical research market. In January 2025, mandatory technical standard NTON 24001 entered into force — a device registration and classification standard that groups human-use medical devices into four risk classes (I–IV). NTON 24001 governs device registration and market controls; it is not a standalone clinical-trial regime.
For FIH device studies, sponsors document ISO 14155 compliance, secure MINSA/ANRS authorization and investigational device import controls, and obtain ethics approval from an Institutional Ethical Review Committee (CIRE) under the General Healthcare Law. Protocols follow ISO 14155 and the Declaration of Helsinki.
bioaccess® manages the complete pathway in Nicaragua — MINSA/ANRS coordination, import authorization, CIRE ethics submissions, site qualification, and monitoring — so sponsors get FDA-quality first-in-human data at roughly 30% lower cost than a comparable US or EU program. Nicaragua fits well within multi-country LATAM programs and for sponsors valuing the newly modernized 2025 device standard.
Nicaragua's Ministry of Health (MINSA) is the national health authority, and the National Health Regulation Authority (ANRS) operates under MINSA as the competent regulatory body for health products, including medical devices. bioaccess® prepares complete regulatory dossiers and coordinates directly with MINSA/ANRS through study start-up.
Since January 2025, human-use medical devices in Nicaragua have been registered under mandatory technical standard NTON 24001, which classifies devices into four risk classes (I–IV). NTON 24001 is a device registration and classification standard — not a clinical-trial regime. Sponsors documenting ISO 14155 compliance use it together with MINSA/ANRS authorization and investigational device import controls to enable FIH studies.
Ethics oversight for clinical research in Nicaragua is carried out by an Institutional Ethical Review Committee (CIRE) under the country's General Healthcare Law. Reviews follow ISO 14155 and the Declaration of Helsinki. bioaccess® coordinates CIRE submissions, manages committee questions, and ensures informed consent documents meet international standards.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Nicaragua for IDE submissions and marketing applications when studies are conducted under ISO 14155 with proper MINSA/ANRS authorization and CIRE ethics approval. bioaccess® designs every protocol for FDA submission from day one — with source data verification, monitoring plans, and documentation practices built around 21 CFR expectations.
| Metric | Nicaragua 🇳🇮 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Device registration standard | NTON 24001 (2025), classes I–IV | 21 CFR 812 | EU MDR |
| Regulatory authority | MINSA / ANRS | FDA | EMA / national CAs |
| Ethics review | Institutional Ethical Review Committee (CIRE) | IRB | Per-country EC |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Cost vs. US program | ~30% lower | Baseline | ~15–25% lower |
| Time zone vs. US | Central (CST) | Same/near | +6 to +9 hours |
Regulatory details reflect published national frameworks; timelines and costs vary by device complexity, therapeutic area, and monitoring requirements. bioaccess® confirms the current pathway for each program.
The Ministry of Health (MINSA) is the national health authority, and the National Health Regulation Authority (ANRS) operates under MINSA as the competent body for medical devices and health products.
NTON 24001 is Nicaragua's mandatory technical standard for the registration and risk classification (Classes I–IV) of human-use medical devices, in effect since January 2025. It governs device registration — not clinical-trial conduct. FIH sponsors combine NTON 24001 device controls with ISO 14155 compliance, MINSA/ANRS authorization, investigational device import controls, and CIRE ethics approval.
Ethics oversight is carried out by an Institutional Ethical Review Committee (CIRE) under the General Healthcare Law, following ISO 14155 and the Declaration of Helsinki.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Nicaragua when studies are conducted under ISO 14155 with proper MINSA/ANRS authorization and CIRE ethics approval. bioaccess® designs protocols for FDA submission from the start.
Nicaragua programs typically run ~30% lower than a comparable US or EU program. Actual cost depends on device complexity, indication, monitoring intensity, and sample size — bioaccess® scopes each program individually.
Nicaragua combines a newly modernized 2025 device standard (NTON 24001), a defined MINSA/ANRS regulatory pathway, CIRE ethics review under ISO 14155, and ~30% lower program cost than US/EU baselines. It's a strong option for multi-country LATAM programs and cost-conscious FIH strategies.
All countries we serve · Contact bioaccess® · First-in-Human CRO